FundingWith a €6.26M round, QLi5 doubles down on proteasome-based ADC payloadsQLi5 Therapeutics has completed a €6.26 million capital increase led by its Korean co-founder, Qurient, which has also increased its voting stake in the German biotech. The funding will be used to … more ➔
photo credit: BioInnovation Institute/Esben Zøllner OlesenInvestmentNovo Nordisk Foundation commits DKK 5.5 billion to scale European biotech innovationThe Novo Nordisk Foundation has committed up to DKK 5.5 billion (€736 million) to the BioInnovation Institute (BII), a Copenhagen-based hub for life science and deep tech entrepreneurship. The long-term … more ➔
CDC.govHerpes VirusMunich’s Innovative Molecules signs €125M partnership with Alfasigma to advance HSV encephalitis antiviralMunich-based Innovative Molecules steps into the spotlight with a partnership with Italy’s Alfasigma. The deal brings fresh capital and a global licence for adibelivir, a next-generation antiviral … more ➔
TQ Therapeutics GmbHCell therapiesFaster to the bedside: Collaboration in cell therapy of Fresenius Kabi and TQ TherapeuticsFresenius Kabi and TQ Therapeutics have entered into a strategic development agreement in cell and gene therapy. Fresenius Kabi receives an exclusive licence to develop, manufacture and distribute products … more ➔
BioNTech SEBioNTech2026: A year of reckoning for BioNTechFor BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook … more ➔
M&AEli Lilly-Abivax €15 billion takeover rumor stirs markets, but no formal steps confirmedWhile much of the biotech industry is focused on meetings and dealmaking at the J.P. Morgan (JPM) Healthcare Conference, a rumor has cut through the JPM noise. The possibility of Eli Lilly making a move … more ➔
Fundingbit.bio closes a $50 million series C round after its 2025 restructuringbit.bio has raised $50 million in a series C round led by M&G Investments to support the next phase of its human cell programming business. The Cambridge-based company develops defined human cells using … more ➔
RocheRocheSecond time around: Roche’s return to MediLink underlines the value of the first dealRoche is back in China — and this time at a very different price point. In a renewed partnership with MediLink Therapeutics, the Swiss pharmaceutical group has secured a second antibody–drug conjugate … more ➔
Freepik.comJohnson & JohnsonNumab’s billion-dollar antibody deal takes an unexpected turnJust over a year and a half ago, Swiss biotech Numab AG, based in Horgen on Lake Zurich, made the headlines when it sold a single antibody to Johnson & Johnson for US$1.25 billion via a spin-out vehicle. … more ➔
Bayer AGCovid-19Better late than never: Bayer eyes a slice of the mRNA vaccine piePatent disputes are part of everyday life in pharma. What is unusual is the timing. More than three years after the peak of the Covid-19 pandemic, Bayer has launched a broad patent offensive against … more ➔
photo credit: BioInnovation Institute/Esben Zøllner Olesen
CDC.gov
TQ Therapeutics GmbH
BioNTech SE
Roche
Freepik.com
Bayer AG